Metagenomi (NASDAQ:MGX) (NASDAQ: MGX) is a biotechnology company dedicated to the discovery and development of novel gene editing tools derived from metagenomic data. Leveraging proprietary artificial intelligence and bioinformatic platforms, the company searches through vast environmental DNA datasets to identify and characterize unique CRISPR-associated (Cas) enzymes. Metagenomi’s approach aims to expand the toolbox of gene editing by uncovering enzymes with enhanced specificity, reduced off-target activity and novel editing capabilities beyond those offered by existing CRISPR systems.
The company’s core business activities include the licensing of newly discovered Cas enzymes to pharmaceutical and biotechnology partners, as well as the in-house development of advanced gene editing solutions for therapeutic and agricultural applications. Metagenomi collaborates with leading industry players to co-develop targeted therapies for genetic disorders and to engineer crop traits that enhance yield, disease resistance and environmental resilience. Its technology platform is designed to streamline the enzyme discovery process and accelerate the translation of research into commercial products.
Headquartered in Berkeley, California, Metagenomi maintains research collaborations and partnerships across North America, Europe and Asia. The company operates a state-of-the-art laboratory facility where multidisciplinary teams of molecular biologists, computational scientists and protein engineers work to validate and optimize novel gene editing tools. Metagenomi’s global network enables it to tailor solutions to diverse markets, from human health to sustainable agriculture, while ensuring compliance with evolving regulatory standards.
Founded in 2018, Metagenomi is led by CEO Haley Warfel, who brings experience in genetic engineering and strategic alliances, alongside a seasoned executive team with backgrounds in genomics, drug development and business development. Since its inception, the company has advanced multiple Cas enzyme candidates through preclinical validation and established strategic collaborations that underscore its position at the forefront of next-generation gene editing innovation.
